A team of scientists at Cold Spring Harbor Laboratory (CSHL) has laid bare the mechanism behind a phenomenon called oncogene addiction in mice suffering from a form of leukemia that mimics acute myelogenous leukemia (AML) in humans.
Significantly, the team was able to mobilize their newly gained understanding to target "addiction" pathways in the model mice, resulting in rapid and complete eradication of the cancer, which is usually fatal and resistant to conventional chemotherapy.
Oncogene addiction refers to the curious phenomenon that cancer cells, despite harboring many genetic alterations, can remain dependent on the continuing expression of a single aberrant, cancer-promoting gene – an oncogene. In this case, the gene in question, called MLL, has long been implicated in human cancers of the blood. In AML, as a result of a genetic anomaly, the protein expressed by the MLL gene fuses with another protein, to form a fusion oncoprotein called MLL-AF9. It is this protein to which AML cancer cells are "addicted."
"The crucial questions are what MLL-AF9 enables cancer cells to do, and how we might intervene to suppress these effects – in other words, how to use our knowledge of the mechanism behind the cancer cell's addiction for developing highly specific anti-cancer therapies.," says CSHL Adjunct Professor and HHMI Investigator Scott W. Lowe, who directed the research, which is reported in a paper that appears August 1 in the journal Genes & Development. "Until now, we've not been able to answer these questions in living animals."
The team's research demonstrated that MLL-AF9 enforces a cellular program that enables blood cells to keep renewing themselves, rather than progressing through the usual stages of cellular life, and eventually dying. While this property of aberrant self-renewal has been a known characteristic of leukemia cells for many years, Lowe and his CSHL colleagues were able to decipher the underlying genetic program in unprecedented detail. The central player orchestrating these cancer-specific self-renewal programs was found to be Myb, a protein known to regulate normal blood cell production that previously also has been implicated in certain subtypes of leukemia.
"MLL-AF9 apparently 'hijacks' Myb to enforce a program of aberrant self-renewal," explains Amy Rappaport, who was a co-first author on the paper, with Johannes Zuber. The team also included Christopher Vakoc, a CSHL Fellow, among others. "The consequences of inhibiting Myb in established leukemia were striking," says Zuber. "Following Myb suppression, mouse leukemia cells invariably lost their aberrant self-renewal ability, resumed their normal cell fate, maturing into white blood cells, and eventually got eliminated." As a consequence, mice harboring this aggressive and chemotherapy-resistant form of AML were cured by inhibiting Myb. The protein's suppression had no adverse impact upon normal white blood cells.
To identify and study genes that are specifically required in cancer cells, the researchers took a systematic approach that demonstrates the power of a series of technological advances made by Lowe's group in concert with several other groups at CSHL. These advances play an important role in CSHL's new Cancer Therapeutic Initiative. The Initiative aims to rapidly identify new therapeutic targets and validate them in mouse models specific for genetic subtypes of human cancer.
In the paper published today, Lowe's team first implemented a rapid strategy to introduce common human AML mutations in mice so that they closely mimicked human AML, both in terms of symptoms and response to treatment. These genetically reprogrammed mice are called "mosaic mice." As a next step, the team used a genetic switch to inactivate the oncogene that gives rise to the "addictive" MLL-AF9 oncoprotein. When MLL-AF9 was suppressed in living mice, the cancers shrank and were soon eliminated altogether from all affected organs. This result confirmed the cancer cells' addiction to MLL-AF9, and provided a unique system to reveal the underlying genetic networks.
To further explore components of these networks, the team used RNA interference, or RNAi, an experimental tool to suppress gene function, which in prior work they had adapted for use in animal models. These recent advances now provide a means to switch off virtually any gene in an established cancer, and thereby enable the identification and evaluation of new potential drug targets. While the current study focused on the dramatic effects of suppressing Myb in AML, the approach validates a general method for understanding oncogene addiction in vivo that can be applied in other cancer types.
The RNA interference technique used in the experiments to block Myb is not applicable in humans, for a variety of still-daunting technical reasons. The hope is to find a small molecule that specifically targets the Myb protein, which can be the basis for a human drug. None has yet been developed, although the search is on.
But, says Lowe, "our results show that suppressing a single mediator of aberrant self-renewal can re-establish pre-existing cell-fate programs and eliminate aggressive AML. This suggests that pre-existing cell-fate programs remain hard-wired even in cancer cells, and raises our hope that agents that inhibit these programs will be less prone to resistance mechanisms that prevent targeted therapies from producing a lasting effect in other cancers."
"An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance" appears August 1 in Genes & Development. The authors are: Johannes Zuber, Amy R. Rappaport, Weijun Luo, Eric Wang, Chong Chen, Angelina V. Vaseva, Junwei Shi, Susann Weissmueller, Meredith J. Taylor, Martina Weissenboeck, Thomas G. Graeber, Scott C. Kogan, Christopher R. Vakoc and Scott W. Lowe. The paper is available online at: http://www.genesdev.org/cgi/doi/10.1101/gad.17269211.
This work was supported by a Specialized Center of Research Grant from the Leukemia and Lymphoma Society, the NIH, and generous gifts from the Don Monti Memorial Research Foundation. Other support was obtained from the German Research Foundation, the Andrew Seligson Memorial Fellowship at CSHL; the Barbara McClintock fellowship; the Leslie Rutherford Leukemia and Lymphoma Society Scholarship; the Cold Spring Harbor President's Council; and the Howard Hughes Medical Institute.
Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 400 scientists strong and its Meetings & Courses program hosts more than 8,000 scientists from around the world each year. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island.
Peter Tarr | EurekAlert!
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research